CD202b / TIE2 / TEK (Tyrosine Kinase with Ig and EGF Homology Domains 2) Antibody [TEK/9412]

• Tyrosine-protein kinase that acts as cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. Required for normal angiogenesis and heart development during embryogenesis. Required for post-natal hematopoiesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Signaling is modulated by ANGPT2 that has lower affinity for TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but inhibits ANGPT1-mediated signaling by competing for the same binding site. Signaling is also modulated by formation of heterodimers with TIE1, and by proteolytic processing that gives rise to a soluble TEK extracellular domain. The soluble extracellular domain modulates signaling by functioning as decoy receptor for angiopoietins. TEK phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1.

• Pan, Xu et al. “Tumour vasculature at single-cell resolution.” Nature vol. 632,8024 (2024): 429-436. doi:10.1038/s41586-024-07698-1
• Akwii, Racheal G et al. “Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology.” Cells vol. 8,5 471. 17 May. 2019, doi:10.3390/cells8050471
• Karabid, Ninelia Minaskan et al. “Angpt2/Tie2 autostimulatory loop controls tumorigenesis.” EMBO molecular medicine vol. 14,5 (2022): e14364. doi:10.15252/emmm.202114364

• https://pubmed.ncbi.nlm.nih.gov/38987599/
• https://pubmed.ncbi.nlm.nih.gov/31108880/
• https://pubmed.ncbi.nlm.nih.gov/34797559/
• https://pubmed.ncbi.nlm.nih.gov/28719590/
• https://pubmed.ncbi.nlm.nih.gov/25470051/
• https://pubmed.ncbi.nlm.nih.gov/33795432/
• https://pubmed.ncbi.nlm.nih.gov/34963058/
• https://pubmed.ncbi.nlm.nih.gov/11191051/
• https://pubmed.ncbi.nlm.nih.gov/35181412/

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

7010

Q02763

9p21.2

65kDa

TEK, Angiopoietin 1 receptor antibody; Angiopoietin-1 receptor antibody; CD202b antibody; CD202b antigen antibody; Endothelial tyrosine kinase antibody; Endothelium specific receptor tyrosine kinase 2 antibody; hTIE 2 antibody; hTIE2 antibody; Hyk antibody; p140 TEK antibody; Soluble TIE2 variant 1 antibody; Soluble TIE2 variant 2 antibody; Tek antibody; tek tyrosine kinase antibody; TEK tyrosine kinase endothelial antibody; tek tyrosine kinase, endothelial antibody; TIE 2 antibody; TIE2 antibody; TIE2_HUMAN antibody; Tunica interna endothelial cell kinase antibody; Tyrosine kinase with Ig and EGF homology domains 2 antibody; Tyrosine kinase with Ig and EGF homology domains-2 antibody; Tyrosine protein kinase receptor TEK antibody ;Tyrosine protein kinase receptor TIE 2 antibody; Tyrosine-protein kinase receptor TEK antibody; Tyrosine-protein kinase receptor TIE-2 antibody; Venous malformations multiple cutaneous and mucosal antibody; VMCM 1 antibody VMCM antibody; VMCM1 antibody, TIE2; VMCM; GLC3E; TIE-2; VMCM1; CD202B